Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 17(2); 2017 > Article
Review Article Application of CRISPR/Cas9 in Treating Hepatitis B Virus
Ju-Yeon Cho
Journal of Liver Cancer 2017;17(2):111-116
DOI: https://doi.org/10.17998/jlc.17.2.111
Published online: September 30, 2017
Department of Internal Medicine, Chosun University School of Medicine, Gwangju, Korea
Corresponding author:  Ju-Yeon Cho,
Email: jy.cho@chosun.ac.kr
  • 3,169 Views
  • 106 Download
  • 0 Crossref
  • 0 Scopus

The advent of oral antiviral agents has revolutionized hepatitis B treatment. It has led to decreased incidence and mortality related to hepatocellular carcinoma. However, although nucleos(t)ide analogs (NA) are fast and potent in inhibiting hepatitis B virus (HBV) polymerase and reverse transcriptase activity, complete cure of the virus is not possible. The complete eradication of HBV requires the covalently-closed-circular DNA (cccDNA) to be eliminated. Novel gene editing methods, such as zing finger nucleases, transcription activator-like effector nucleases, and the clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/ Cas9) system, designed to target specific DNA sequences has great potential for therapeutic application. Among these, the CRISPR/Cas9 system may be the most feasible approach to eradicate HBV cccDNA. Further studies are needed to develop a more efficient and safer
method
of delivery using the CRISPR/Cas9 system to achieve complete cure of chronic hepatitis B.

Related articles

JLC : Journal of Liver Cancer